Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00442689 · ClinicalTrials.gov registry record · NA

Metabolic Syndrome in PCOS: Precursors and Interventions

A NA study of Metabolic Syndrome and Polycystic Ovary Syndrome, sponsored by Northwestern University.

Completed
Registry status
NA
Development phase
97
Enrollment target
1
Study location

NCT00442689 is a NA study of Metabolic Syndrome and Polycystic Ovary Syndrome that has completed, run by Northwestern University. The registered enrollment target is 97 participants, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00442689, a NA study of Metabolic Syndrome and Polycystic Ovary Syndrome, has completed, sponsored by Northwestern University.

COMPLETED
Registry status
NA
Development phase
97 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to investigate the metabolic effects of anti-androgens and oral contraceptive pills (OCPs), compared with placebo, in the treatment of women with PCOS. We hypothesized that controlling elevated androgen levels with either anti-androgens or OCPs would produce improvement in metabolic markers in PCOS women and would reduce their long term metabolic risk.

Interventions

  • OTHER placebo
  • DRUG flutamide
  • DRUG ethinyl estradiol 35 mcg and drospirenone 3 mg

Study Locations (1)

Illinois

  • Northwestern Memorial Hospital - Chicago

Trial Details

FieldValue
Enrollment Target 97 participants
Start Date 2006-07
Est. Completion 2012-11
Phase NA

Sponsor

Northwestern University

1,209 total trials

What the Registry Record Tells You About NCT00442689

The ClinicalTrials.gov registry entry for NCT00442689 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,204-participant average among 102 other Metabolic Syndrome trials with a reported enrollment target (92% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metabolic Syndrome appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.

NCT00442689 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT00442689 about?

NCT00442689 is a clinical study titled "Metabolic Syndrome in PCOS: Precursors and Interventions". The purpose of this study is to investigate the metabolic effects of anti-androgens and oral contraceptive pills (OCPs), compared with placebo, in the treatment of women with PCOS. We hypothesized that controlling elevated androgen levels with either anti-androgens or OCPs would produce improvement ...

What is the current status of trial NCT00442689?

This trial is currently completed. It is a NA study. The enrollment target is 97 participants. The study started on 2006-07. Estimated completion is 2012-11.

What conditions does trial NCT00442689 study?

This clinical trial studies the following conditions: Metabolic Syndrome, Polycystic Ovary Syndrome.

What interventions are being tested in trial NCT00442689?

The interventions under investigation include: placebo (OTHER), flutamide (DRUG), ethinyl estradiol 35 mcg and drospirenone 3 mg (DRUG).

Who is sponsoring clinical trial NCT00442689?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00442689 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolic Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.